Carl J. Danzig

Feb 5, 2024 | healio.com | Alex Young |Christine Klimanskis |Carl J. Danzig

You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study.

Dec 13, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

December 13, 2023Retina experts deliberate on the role of fluorescein angiography in AMD and discuss initiation of anticomplement therapy for geographic atrophy in conjunction with anti-VEGF therapy for neovascular AMD. Arghavan Almony, MD: That was a great case. Let me step back for a second to the diagnosis. We had not 1 but 2 FAs [fluorescein angiograms] in this case. I think a lot of retina specialists are going away from FA more and more for many reasons.

Dec 13, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

Arghavan Almony, MD: We’ll move to our third case. Roger, if you could. Roger Goldberg, MD: I’m pleased to be sharing a case from my good friend and colleague Nate Steinle[, MD] down in Santa Barbara, [California]. This is a patient of his whom he refers to as one of his true VIP patients. [This is] a 71-year-old [woman] with slow-onset blurred vision in both eyes. Here’s the color fundus photo of the right eye, and we see a little bit of [geographic] atrophy present and drusen.

Dec 6, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

Arghavan Almony, MD: Let’s move on to the next case. Adrienne, if you could present this case for us. Adrienne Scott, MD: Thank you very much. This is a patient whom I encountered in my clinic. He’s a 73-year-old man [with] a history of long-standing intermediate AMD [age-related macular degeneration]. He came in acutely, [presenting with] a new onset central scotoma in his right eye for [approximately] 1 week. No symptoms in the left [eye]. He has no positive past ocular history.

Nov 29, 2023 | ophthalmologytimes.com | Arghavan Almony |Adrienne K. Scott |Roger A. Goldberg |Carl J. Danzig

Arghavan Almony, MD: Thank you, Carl. That was a great case. When we talk about cases, they’re [usually] unique cases that we don’t often see, but this is something we see every day in our retina clinics. What is your first-line treatment for a patient with PDR [proliferative diabetic retinopathy]? Carl Danzig, MD: My first-line treatment for a patient with PDR is always anti-VEGF or bispecific. In this case, I chose faricimab as a treatment.